What was the primary driver of Abbott's revenue growth in this quarter?

The primary driver of Abbott's revenue growth in the second quarter of 2010 was the acquisition of Solvay Pharmaceuticals, completed in February 2010. This significantly boosted net sales across the company, particularly within the Pharmaceutical Products segment.

How did the acquisitions impact Abbott's profitability?

While acquisitions like Solvay Pharmaceuticals drove significant revenue growth, they also led to increased operating expenses, including research and development and selling, general, and administrative costs. Net earnings for the quarter remained stable year-over-year at $1.3 billion, indicating that the company managed these increased costs effectively, though the benefit of acquisitions is more evident in top-line growth than immediate net income increase.

What are the key risks or potential headwinds mentioned in the report?

A significant potential risk highlighted is the ongoing patent infringement litigation related to HUMIRA. If Abbott's appeal is unsuccessful, the resolution of this case could materially impact cash flows or results of operations. Additionally, new healthcare reform legislation in the U.S. will introduce new fees and rebate obligations in future periods, potentially affecting gross profit margins.

How is Abbott managing its debt and liquidity, especially given the recent acquisitions?

Abbott generated approximately $3.9 billion in net cash from operating activities in the first six months of 2010, which is expected to exceed capital expenditures and dividends. The company also issued $3.0 billion in long-term debt in Q2 2010 to fund operations and acquisitions. Despite using significant cash for acquisitions, Abbott maintained healthy liquidity, with $6.3 billion in unused credit lines.

ABT 10-Q Quarterly Report Q2 FY2010 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' (ABT) second quarter 2010 report shows robust top-line growth, with net sales increasing by 17.8% to $8.8 billion for the quarter and 16.3% to $16.5 billion for the first six months, largely driven by the significant acquisition of Solvay Pharmaceuticals. This strategic acquisition bolstered the Pharmaceutical Products segment, which saw a 24.5% increase in sales for the quarter. Despite increased operating expenses related to acquisitions and R&D, the company maintained strong profitability, with net earnings for the quarter remaining stable at $1.3 billion year-over-year. The company's cash flow from operations remains healthy, providing resources for ongoing investments and dividends, although a substantial portion of cash was used for acquisitions. Investors should note the ongoing legal proceedings, particularly the patent infringement case related to HUMIRA, which, if unsuccessful on appeal, could materially impact results, though Abbott expresses confidence in its appeal. Abbott Laboratories demonstrated strategic growth through significant acquisitions, most notably Solvay Pharmaceuticals for $6.1 billion, which is expected to expand its global reach. This move, along with other smaller acquisitions like STARLIMS Technologies and Facet Biotech, significantly increased goodwill and intangible assets on the balance sheet. The company also announced its intent to acquire Piramal Healthcare Limited's Healthcare Solutions business for $2.12 billion, signaling continued aggressive expansion. While these acquisitions are driving top-line growth, they also contribute to increased R&D and SG&A expenses. The company continues to return value to shareholders through dividends, increasing them by 10% for the quarter to $0.44 per share.

Financial Highlights

54 data points

Beta

Revenue

$8.83B

0.6% Gross Margin

Net Income

$1.29B

0.1% Net Margin

EPS (Diluted)

$0.83

Total Assets

$53.38B

Cash & Equivalents

$4.32B

Free Cash Flow

$2.07B

Financial Statements

Beta

Revenue	$8.83B
Cost of Revenue	$3.54B
Gross Profit	$5.28B
SG&A Expenses	$2.74B
Operating Expenses	$7.22B
Operating Income	$1.61B
Interest Expense	$134.49M
Net Income	$1.29B
EPS (Basic)	$0.83
EPS (Diluted)	$0.83
Shares Outstanding (Basic)	1.54B
Shares Outstanding (Diluted)	1.55B

Key Highlights

1Net sales for Q2 2010 increased 17.8% to $8.8 billion, and for the first six months rose 16.3% to $16.5 billion, primarily due to the acquisition of Solvay Pharmaceuticals.
2The Pharmaceutical Products segment showed strong growth with a 24.5% increase in sales for Q2 2010, largely driven by the Solvay acquisition.
3Net earnings for Q2 2010 were $1.3 billion, largely flat compared to $1.3 billion in Q2 2009, indicating stable profitability despite increased expenses.
4Abbott completed several significant acquisitions in early 2010, including Solvay Pharmaceuticals for $6.1 billion, and announced an agreement to acquire Piramal Healthcare's business.
5Research and development expenses increased by 28.0% in Q2 2010 and 20.2% year-to-date, reflecting pipeline investment and acquisition-related costs.
6Selling, general, and administrative expenses increased by 35.5% in Q2 2010 and 19.8% year-to-date, impacted by acquisitions and litigation reserves.
7Cash dividends declared per common share increased by 10% to $0.44 for the quarter and 10% to $0.88 for the first six months compared to the prior year.

ABBOTT LABORATORIES Quarterly Report for Q2 Ended Jun 30, 2010

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions